(Q33839025)

29 July 2017

1 reference

title

Cyclophosphamide and other new agents for the treatment of severe aplastic anemia (English)

1 reference

29 July 2017

1 reference

J F Tisdale

1

1 reference

PubMed ID

10676915

29 July 2017

D E Dunn

series ordinal

2

1 reference

PubMed ID

10676915

29 July 2017

J Maciejewski

series ordinal

3

1 reference

29 July 2017

1 January 2000

1 reference

29 July 2017

Seminars in Hematology

1 reference

29 July 2017

37

1 reference

29 July 2017

102-109

1 reference

29 July 2017

1

1 reference

Recovery from aplastic anemia after treatment with cyclophosphamide

29 July 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0037-1963%2800%2990034-9

7 January 2021

Prolongation of Homograft Survival in Mice with Single Doses of Cyclophosphamide

1 reference

https://api.crossref.org/works/10.1016%2FS0037-1963%2800%2990034-9

7 January 2021

T-cell subpopulations in blood and cerebrospinal fluid of multiple sclerosis patients: effect of cyclophosphamide

1 reference

https://api.crossref.org/works/10.1016%2FS0037-1963%2800%2990034-9

7 January 2021

The effect of cyclophosphamide on T lymphocytes and T lymphocyte subsets in patients with chronic progressive multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS0037-1963%2800%2990034-9

7 January 2021

Immunoablative high-dose cyclophosphamide without stem-cell rescue for refractory, severe autoimmune disease

1 reference

https://api.crossref.org/works/10.1016%2FS0037-1963%2800%2990034-9

7 January 2021

Transcription-modulating drugs: mechanism and selectivity

1 reference

https://api.crossref.org/works/10.1016%2FS0037-1963%2800%2990034-9

7 January 2021

Antithymocyte globulin treatment in patients with aplastic anemia: a prospective randomized trial

1 reference

https://api.crossref.org/works/10.1016%2FS0037-1963%2800%2990034-9

7 January 2021

Paroxysmal nocturnal hemoglobinuria cells in patients with bone marrow failure syndromes

1 reference

https://api.crossref.org/works/10.1016%2FS0037-1963%2800%2990034-9

7 January 2021

Treatment of aplastic anemia with antilymphocyte globulin and methylprednisolone with or without cyclosporine. The German Aplastic Anemia Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0037-1963%2800%2990034-9

7 January 2021

Oral cyclosporin-A is effective treatment for untreated and also for previously immunosuppressed patients with severe bone marrow failure

1 reference

https://api.crossref.org/works/10.1016%2FS0037-1963%2800%2990034-9

7 January 2021

Glucocorticoids and cyclosporine induce apoptosis in mitogen-activated human peripheral mononuclear cells

1 reference

https://api.crossref.org/works/10.1016%2FS0037-1963%2800%2990034-9

7 January 2021

Mycophenolate mofetil and tacrolimus as primary maintenance immunosuppression in simultaneous pancreas-kidney transplantation: initial experience in 50 consecutive cases

1 reference

https://api.crossref.org/works/10.1016%2FS0037-1963%2800%2990034-9

7 January 2021

Cyclosporine therapy of aplastic anaemia, congenital and acquired red cell aplasia

1 reference

https://api.crossref.org/works/10.1016%2FS0037-1963%2800%2990034-9

7 January 2021

Increased expression of Fas antigen on bone marrow CD34+ cells of patients with aplastic anaemia

1 reference

https://api.crossref.org/works/10.1016%2FS0037-1963%2800%2990034-9

7 January 2021

Partial T-cell activation and anergy induction by polyclonal antithymocyte globulin.

1 reference

https://api.crossref.org/works/10.1016%2FS0037-1963%2800%2990034-9

7 January 2021

Correlation of clinical and immunologic states in multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS0037-1963%2800%2990034-9

7 January 2021

Administration of monthly-pulse cyclophosphamide in multiple sclerosis patients. Effects of long-term treatment on immunologic parameters

1 reference

https://api.crossref.org/works/10.1016%2FS0037-1963%2800%2990034-9

7 January 2021

Randomised trial of basiliximab versus placebo for control of acute cellular rejection in renal allograft recipients. CHIB 201 International Study Group.

1 reference

https://api.crossref.org/works/10.1016%2FS0037-1963%2800%2990034-9

7 January 2021

Proportional increase in the theta carrying lymphocytes in peripheral lymphoid tissue following treatment with cyclophosphamide.

1 reference

https://api.crossref.org/works/10.1016%2FS0037-1963%2800%2990034-9

7 January 2021

Lymphocyte phenotype and lymphokines following anti-thymocyte globulin therapy in patients with aplastic anaemia

1 reference

https://api.crossref.org/works/10.1016%2FS0037-1963%2800%2990034-9

7 January 2021

A comprehensive definition of the major antibody specificities in polyclonal rabbit antithymocyte globulin

1 reference

https://api.crossref.org/works/10.1016%2FS0037-1963%2800%2990034-9

7 January 2021

Cyclophosphamide-sensitive T lymphocytes suppress the in vivo generation of antigen-specific cytotoxic T lymphocytes

1 reference

https://api.crossref.org/works/10.1016%2FS0037-1963%2800%2990034-9

7 January 2021

Relapse of aplastic anaemia after immunosuppressive treatment: a report from the European Bone Marrow Transplantation Group SAA Working Party

1 reference

https://api.crossref.org/works/10.1016%2FS0037-1963%2800%2990034-9

7 January 2021

Rapamune® (RAPA, rapamycin, sirolimus): mechanism of action immunosuppressive effect results from blockade of signal transduction and inhibition of cell cycle progression

1 reference

https://api.crossref.org/works/10.1016%2FS0037-1963%2800%2990034-9

7 January 2021

Interferon-gamma and tumor necrosis factor-alpha suppress both early and late stages of hematopoiesis and induce programmed cell death

1 reference

https://api.crossref.org/works/10.1016%2FS0037-1963%2800%2990034-9

7 January 2021

A prospective, randomized trial of tacrolimus/prednisone versus tacrolimus/prednisone/mycophenolate mofetil in renal transplant recipients

1 reference

https://api.crossref.org/works/10.1016%2FS0037-1963%2800%2990034-9

7 January 2021

Malignant tumors occurring after treatment of aplastic anemia. European Bone Marrow Transplantation-Severe Aplastic Anaemia Working Party

1 reference

https://api.crossref.org/works/10.1016%2FS0037-1963%2800%2990034-9

7 January 2021

The IL-2/IL-2 receptor system: a current overview

1 reference

https://api.crossref.org/works/10.1016%2FS0037-1963%2800%2990034-9

7 January 2021

Antilymphocyte immunoglobulins stimulate peripheral blood lymphocytes to proliferate and release lymphokines

1 reference

https://api.crossref.org/works/10.1016%2FS0037-1963%2800%2990034-9

7 January 2021

Treatment of vasculitis

1 reference

https://api.crossref.org/works/10.1016%2FS0037-1963%2800%2990034-9

7 January 2021

Mechanism of action of antithymocyte globulin in the treatment of aplastic anaemia: in vitro evidence for the presence of immunosuppressive mechanism

1 reference

https://api.crossref.org/works/10.1016%2FS0037-1963%2800%2990034-9

7 January 2021

Autologous Bone Marrow Repopulation following High Dose Cyclophosphamide and Allogeneic Marrow Transplantation in Aplastic Anaemia

1 reference

https://api.crossref.org/works/10.1016%2FS0037-1963%2800%2990034-9

7 January 2021

Late haematological complications in severe aplastic anaemia

1 reference

https://api.crossref.org/works/10.1016%2FS0037-1963%2800%2990034-9

7 January 2021

Daclizumab: outcome of phase III trials and mechanism of action. Double Therapy and the Triple Therapy Study Groups

1 reference

https://api.crossref.org/works/10.1016%2FS0037-1963%2800%2990034-9

7 January 2021

Differential cyclophosphamide sensitivity of suppressor and cytotoxic cell precursors

1 reference

https://api.crossref.org/works/10.1016%2FS0037-1963%2800%2990034-9

7 January 2021

10.1016/S0037-1963(00)90034-9

Identifiers

DOI

1 reference

29 July 2017

1 reference

PubMed ID

10676915